Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously published in the New England Journal of Medicine (NEJM), finds at up to 10 ...

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer Electronic patient self-Reporting of Adverse ...

Because of advances in hematopoietic cell transplant (HCT), meeting the long-term health needs of increasing numbers of HCT survivors remains challenging. This multicenter trial aimed to assess the ...

医疗AI的临床价值，需以“安全、有效、实用”为核心标尺。为突破当前医疗模型验证碎片化、场景适配差的痛点，研究团队创新设计逻辑闭环、覆盖全面的三步递进式验证策略(见图2)，从“基础安全”到“场景适配”，再到“临床实效”，层层筑牢模型临床落地的证据根基，最大化保障其在真实诊疗场景中的可靠性与适配性。

This 56-week, randomized, placebo-controlled trial aimed to evaluate the efficacy and safety of 3.0 mg of liraglutide, injected subcutaneously once daily, as an adjunct to a reduced-calorie diet ...

In this randomized, controlled trial involving patients with very high use of health care services, readmission rates were not lower among patients randomly assigned to the Coalition’s program ...

Because of ethical considerations, scientists haven’t been able to conduct randomized controlled trials to conclusively prove the effectiveness of mask-wearing on interrupting coronavirus ...